Celgene Corporation (NASDAQ:CELG) announced that its direct wholly-owned subsidiary, Strix Corporation, has commenced its previously announced tender offer for all outstanding shares of …
In a research report issued Friday, Canaccord Genuity analyst John Newman reiterated a Buy rating on Celgene Corporation (NASDAQ:CELG) and raised the price target …
J.P.
Celgene Corporation (NASDAQ:CELG) reported net product sales of $2,254 million for the second quarter of 2015, a 22 percent increase from the same period …
Piper Jaffray’s healthcare analyst Joshua Schimmer weighed in today with a favorable report on Celgene Corporation (NASDAQ:CELG), raising the price target to $160 (from …
Cowen and Co.’s Eric Schmidt covers several companies in the biotechnology sector.
Oncology therapy company Celgene Corporation (NASDAQ:CELG) announced a definitive agreement on July 14 to acquire Receptos Inc (NASDAQ: RCPT). Under the terms of …
In a research report issued today, Canaccord Genuity analyst John Newman raised his earnings estimates for Celgene Corporation (NASDAQ:CELG) based on higher 2015 and 2020 …
Healthcare investors can sleep easy tonight with one of 2015’s major unanswered questions now off the table. Celgene Corporation (NASDAQ:CELG) will buy Receptos …
Celgene Corporation (NASDAQ:CELG)’s proposed $7.2 billion acquisition of Receptos Inc (NASDAQ:RCPT) would bring the pharmaceutical giant a potential blockbuster product candidate, Ozanimod, currently in Phase 3 development for the …
